Search

Displaying results 2901 - 2910 of 10000 in total
  1. Drug

    Mesoridazine

    go.drugbank.com/drugs/DB00933
    ApprovedWithdrawn

    A phenothiazine antipsychotic with effects similar to chlorpromazine.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  2. Drug

    Trypsin

    go.drugbank.com/drugs/DB11237
    ApprovedInvestigationalVet approved

    Trypsin is a serine protease that plays an essential role in protein hydrolysis and absorption in mammals. … When converted from its zymogen trypsinogen, trypsin is available as an active peptide hydrolase (EC 3.4.21.4) form to cleave peptide chains, mainly at the carboxyl side of the amino acids lysine or arginine

  3. Drug

    Aleglitazar

    go.drugbank.com/drugs/DB08915
    Investigational

    Aleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … Aleglitazar is an agonist at the peroxisome proliferator-activated receptor (PPAR) for both the PPARα and PPARγ receptor subtypes.

  4. Drug

    FM-VP4

    go.drugbank.com/drugs/DB05449
    Investigational

    FM-VP4, is a novel hydrophilic phytostanol analogue representing a new class in cholesterol-lowering drugs called cholesterol absorption inhibitors. … FM-VP4 has been shown to inhibit cholesterol absorption and to lower plasma LDL-cholesterol and total cholesterol in a broad range of animal species.

  5. Drug

    Anisotropine methylbromide

    go.drugbank.com/drugs/DB00517
    Approved

    Anisotropine methylbromide is a quaternary ammonium compound. Its use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … Depending on the dose, anisotropine methylbromide may reduce the motility and secretory activity of the gastrointestinal system, and the tone of the ureter and urinary bladder and may have a slight relaxant

  6. Drug

    Loncastuximab tesirine

    go.drugbank.com/drugs/DB16222
    ApprovedInvestigational

    Relapsed and refractory B-cell acute lymphoblastic leukemia (B-ALL) are a therapeutic challenge for patients who have undergone prior systemic therapies with limited success. … [A234444] On April 23 2021, the Food and Drug Administration granted accelerated approval for the antibody-drug conjugate, loncastuximab tesirine-lpyl, also known as Zynlonta.

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: Humanized monoclonal immunoglobulin G1 antibody directed against human CD19 conjugated to SG3199 through A protease cleavable valine-alanine linker
  7. Drug

    Streptococcus pneumoniae type 2 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10320
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 2 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 2 of *Streptococcus pneumoniae*.

  8. Drug

    Streptococcus pneumoniae type 8 capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10326
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 8 capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 8 of *Streptococcus pneumoniae*.

  9. Drug

    Streptococcus pneumoniae type 10a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10329
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 10a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 10a of *Streptococcus pneumoniae

  10. Drug

    Streptococcus pneumoniae type 11a capsular polysaccharide antigen

    go.drugbank.com/drugs/DB10330
    ApprovedInvestigational

    It is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia. … Streptococcus pneumoniae type 11a capsular polysaccharide antigen is a vaccine that contains highly purified capsular polysaccharides from the invasive pneumococcal type 11a of *Streptococcus pneumoniae